Search the Newsreel

Sapient Capital LLC Sells 43,998 Shares of Sprott Inc. $SII

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Here's Why

Protagonist Therapeutics (NASDAQ:PTGX) recently achieved a new 52-week high of $151.88, closing at $148.29, driven by strong analyst sentiment and exceeding quarterly earnings expectations. The company reported $2.29 EPS against a $2.27 estimate and a significant 3,746.8% year-over-year revenue surge to $213.47 million. Despite …

Sprott Inc (SII) Earnings Forecast: Future EPS & Revenue Growth Estimates

INTELLIGENT PROTECTION MANAGEMENT ($IPM) Releases Q2 2026 Earnings

Intelligent Protection Management earnings missed by $0.12, revenue fell short of estimates

Is Intelligent Protection Management Corp (IPM) Overvalued After

Intelligent Protection Management Q2 2026 Earnings Call Transcript

Intelligent Protection (Nasdaq: IPM) grows Q2 2026 revenue but widens loss

Proto Labs (PRLB) Is Up 11.7% After Raising 2026 Revenue Guidance And Highlighting Rising Customer Spend

In late July 2026, Proto Labs, Inc. reported past second-quarter results showing sales of US$149.34 million and net income of US$9.15 million, alongside raising its full-year 2026 revenue growth guidance to 8%–10% and issuing new third-quarter earnings guidance. Management highlighted a 17% year-over-year increase …

Intelligent Protection Management Corp. Reports Second Quarter 2026 Financial Results

Prothena files initial beneficial ownership statement for Todd W. Fennell

Prothena has filed an initial beneficial ownership statement (Form 3) for Todd W. Fennell, who is listed as a 10% owner. The filing, dated August 6, 2026, indicates that Fennell beneficially owns no securities, with no non-derivative or derivative holdings reported. The form was …

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results

Protara Therapeutics (NASDAQ:TARA) announced its quarterly earnings, reporting a loss of $0.36 per share, which missed the consensus estimate by $0.03. Despite the earnings miss and stock performance, analysts maintain a "Moderate Buy" consensus with an average price target of $26.25. Institutional investors like …

Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals

HC Wainwright Issues Positive Estimate for Prothena Earnings

Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary

Protara Therapeutics, Inc. (TARA) reported a wider net loss of $(21.7)M for Q2 2026, with an EPS of $(0.36), compared to the previous year, as the company increased investments in clinical programs and operational expansion. Key business highlights include advancements in the Phase 2 …

Sprott Focus Trust, Inc. Revenue Breakdown – BOATS:FUND

Sprott Focus Trust, Inc. (FUND) reported its revenue breakdown, with the United States being the largest contributor to its financial performance. The company generated $21.78 million USD from the U.S. last year, a slight increase from $19.77 million USD the previous year. This data …

Sprott Focus Trust, Inc. $FUND Position Boosted by Royal Bank of Canada

Royal Bank of Canada significantly increased its stake in Sprott Focus Trust, Inc. (NASDAQ:FUND) by 15.4% in the first quarter, now owning 802,431 shares valued at $7.655 million. Several other institutional investors also adjusted their positions in the company, with notable increases from Osaic …

Protara Therapeutics: Q2 Earnings Snapshot

Protara Therapeutics, Inc. (TARA) reported a second-quarter loss of $21.7 million, or 36 cents per share, which missed Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of 33 cents per share. This financial update was generated by Automated Insights …

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Protara Therapeutics (Nasdaq: TARA) announced its second-quarter 2026 financial results and provided a business update, highlighting significant progress across its clinical pipeline. The company expects to complete enrollment for its ADVANCED-2 trial in BCG-Unresponsive NMIBC patients and redesign the ADVANCED-3 trial to expand into …

Intelligent Protection Management Corp (IPM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Enterprise value to revenue forward of China Dredging Environment Protection Holdings Limited – HKEX:871

Sprott: Gold and Silver Correction Cyclical, Long-Term Bull Market Intact | 2026 Outlook - News and Statistics

Sprott Inc. views the recent decline in precious metals as a temporary, cyclical correction within an ongoing long-term bull market, not a reversal of the trend. Maria Smirnova, Managing Partner at Sprott, attributes the pullback to cyclical factors rather than weakening fundamentals, emphasizing that …

PTGX (PTGX) insider files to sell 225,000 shares under Rule 144

An insider at Protagonist Therapeutics (PTGX) has filed to sell 225,000 common shares under Rule 144, with an aggregate market value of $33,583,500. The sale will be executed through J.P. Morgan Securities LLC on Nasdaq and is associated with an option exercise. This filing …

Price correction ‘improved the long-term risk-reward profile’ for both gold and silver – Sprott’s Smirnova

Maria Smirnova of Sprott Inc. stated that the recent price correction in gold and silver was a cyclical adjustment within a secular bull market, not a reversal. She highlighted that underlying macroeconomic factors like rising debt, central bank buying, and geopolitical fragmentation continue to …

Wedbush Adjusts PT on Protagonist Therapeutics to $173 From $118, Keeps Outperform Rating

Wedbush has increased its price target for Protagonist Therapeutics (PTGX) to $173 from $118, while maintaining an Outperform rating on the stock. This adjustment reflects a more optimistic outlook from the analyst firm.

Prothena 10% owner William P. Scully buys $293,052 of common shares

William P. Scully, a 10% owner of Prothena, recently purchased 34,000 ordinary shares for $293,052, increasing his direct stake to 790,000 shares. Additionally, Manatee Equity Fund LLC, attributed to Scully, acquired 3,500 shares. Scully's spouse also holds 52,000 ordinary shares indirectly.

Understanding Momentum Shifts in (FUND)

This article analyzes Sprott Focus Trust Inc. (NASDAQ: FUND), highlighting a mid-channel oscillation pattern and a strong 17.0:1 risk-reward setup. It outlines three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis, suggesting strong …

What Makes Proto Labs (PRLB) a Strong Momentum Stock: Buy Now?

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Apogee Adds Joseph Hayek, Suresh Krishna to Board of Directors

Apogee Enterprises Inc. has expanded its board of directors from six to eight members by electing Joseph Hayek and Suresh Krishna as independent directors. Hayek is the president and CEO of Worthington Enterprises Inc., and Krishna is the president and CEO of Proto Labs …

Proto Labs (PRLB) Lifts Outlook As Fair Value Looks Fully Valued

Protagonist upgraded at Goldman Sachs on potential of autoimmune asset

Goldman Sachs upgraded Protagonist Therapeutics (PTGX) to a buy rating from neutral, setting a price target of $186. The upgrade is driven by the promising potential of the company's phase 1 oral IL-17 antagonist, PN-881, which is being developed for various autoimmune conditions. This …

Goldman Sachs Upgrades Protagonist Therapeutics to Buy From Neutral, Adjusts PT to $186 From $110

Goldman Sachs has upgraded Protagonist Therapeutics (PTGX) to a "Buy" rating from "Neutral" and increased its price target to $186 from $110. The article also notes that Protagonist Therapeutics has an average rating of "Buy" and a mean price target of $159.36 from other …

PROTAGONIST THERAPEUTICS, INC. : WEDBUSH RAISES TARGET PRICE TO $173 FROM $118

Wedbush has increased its target price for Protagonist Therapeutics, Inc. to $173, up from the previous $118. The information is provided by Reuters and indicates a significant positive revision in the analyst's outlook for the company's stock.

Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating

Truist has raised its price target for Protagonist Therapeutics (NASDAQ: PTGX) from $145 to $170, while maintaining a "Buy" rating on the stock. This adjustment reflects a continued positive outlook from the firm on the biopharmaceutical company. Other analysts, including Goldman Sachs and Wedbush, …

Goldman Sachs upgrades Protagonist Therapeutics stock rating on drug potential

Goldman Sachs upgraded Protagonist Therapeutics (NASDAQ:PTGX) to Buy from Neutral, raising its price target to $186 from $110, citing the potential of its oral IL-17 drug, PN-881. The company recently reported strong Q2 2026 financial results, including significant license and collaboration revenue and a …